NCT07052578Recruiting
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A Multicentre Observational Study on Treatment Patterns and ctDNA HRR Evaluation in Aggressive High-volume Metastatic Hormone-sensitive Prostate Cancer in Russian Federation
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 230 (estimated)
- First submitted
- 26 Jun 2025
- Start date
- 30 Jun 2025
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Prostate cancer
- NCT number
- NCT07052578
What you commit to
- Study type: Observational
- Planned participants: 230
- From 30 Jun 2025 to the primary completion date, 31 Dec 2027
- 24 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participation in any interventional trial since the mPC diagnosis.
- Progression to mCRPC.
Who the study is looking for
- Male patients aged ≥ 18 years old;
- Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing;
- Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages);
- High-aggressive disease (Gleason 8-10);
- High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis);
- Availability of source medical documentation;
- Known HRRm status based on routine tumour sample analysis.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (24)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.